This document summarizes the agenda and presentation slides for a Wyeth analyst meeting from October 2006. The agenda included introductions and presentations on new and pipeline products from Wyeth, including Enbrel, Prevnar, Prevnar 13, Tygacil, Torisel, Lybrel, Aprela/Viviant, methylnaltrexone, bifeprunox, and Pristiq. Slides 6-7 showed Wyeth's past business performance with steady revenue and earnings per share growth from 1999-2006, except for impacts from the Women's Health Initiative study in 2002-2003. Slide 8 indicated earnings per share growth was expected to continue growing double-digits in 2006 according to